about
Oral paliperidone for schizophreniaGenomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaSubstance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE studyGenomewide association for schizophrenia in the CATIE study: results of stage 1Comparison of antipsychotic medication effects on reducing violence in people with schizophreniaEffectiveness of switching from antipsychotic polypharmacy to monotherapy.Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.Polypharmacy for schizophrenia.Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.Service use and health status of persons with severe mental illness in full-risk and no-risk medicaid programs.Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Genomewide association study of movement-related adverse antipsychotic effects.Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.Report from the working group conference on multisite trial design for cognitive remediation in schizophreniaNo association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study).Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators.Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study.Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trialPublic-academic partnerships: a rapid small-grant program for policy-relevant research: motivating public-academic partnerships.Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees.Geographic and clinical variation in clozapine use in the United States.Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.Clozapine for Schizophrenia: State Variation in Evidence-Based Practice.Premature Mortality Among Adults With Schizophrenia in the United States.
P50
Q24242948-0ECB59A2-2670-4D75-9E99-F9269D330200Q24630309-B6C4855C-D8BA-4DCF-81A1-B95EB555A635Q28273164-E8416714-78BE-4048-ADF9-2F3D7DC20AB1Q28301780-C9BFB3A5-E735-455A-91E9-0ED7CE300E6DQ28659652-F14B55FA-99C3-4DBE-963F-8B5E48A5137CQ30436445-9E39FD8F-4841-43BC-AFB1-424AE9325BC7Q30542484-256F8A54-7317-4C32-9352-1FA85CBB30E2Q30542486-01403603-6452-4717-A4E4-002745E4A318Q31005816-D22FC4EA-CA88-4BFE-ABE4-9487EFFE24CFQ33288672-0E4DCC5C-6173-4D60-885D-175846008395Q33383396-FE904AF8-65C6-4E29-928E-406FC6650AC6Q33634660-8E0F15B5-F059-495C-9429-830517D97547Q33926334-94CF82FD-8E37-48CC-BABC-E5098474AF9BQ34145251-73C94ED6-E6B3-4EA6-A87C-ADA4444FBF85Q34455790-F0CCD4B5-95AD-4683-919A-16D7EC6041F5Q34550311-C27C9C4C-DD6A-4CE6-A695-09754F40EE77Q34573456-23CD17D0-1DFE-4ACD-A889-301F2C2DFDC4Q34661875-BEF8DE1A-C834-4818-90F8-50DF12533FB5Q35010386-C37EFD7F-9346-4F28-A73B-275EFDE0049FQ35115704-2FA44F53-F000-400C-96F6-4CED5732C583Q35177128-DF385C8E-5271-43A2-B59C-F1CB4E7A0B13Q35234690-2259374A-BA11-42D3-8A79-FCD93AD5ED0AQ35460642-2933D91B-C562-4167-9461-7BF655B5A079Q35846062-AAC68C65-49BD-4482-BBDF-F44F77AACE20Q36414518-5101C922-6DD0-4A8E-97F1-3530A4A6DD63Q36546977-7C6F5164-3B82-4111-8A33-563185B3C9C8Q36973177-DE151969-6535-4B0E-B4DF-B64C0EC04658Q37075725-F0954304-EFED-4DC3-BD19-509EA33D631AQ37095956-159E3E79-6C36-4862-AA98-23303EC25674Q37102317-E8E6CD37-9AD4-4467-9324-0278FC6D47D8Q37172973-97A52555-97D7-43D9-86BE-8FC884FE22AAQ37302639-96EB4C6C-4123-468B-B025-93D6BDFED0BAQ37419789-36FEB856-ED7F-4573-87E9-74445504952DQ37489656-F1B52275-491A-46E6-8181-BD52312E4AEEQ37632703-9DFF46BD-F354-49DE-BE70-467A546F64FFQ38057135-1AFC918B-6524-4DAB-AC2B-D9B0DCF204C1Q38162752-2E48AB41-2433-4E32-9D5B-ADC5A315B998Q40351255-49CF948C-03C4-41D5-90EB-AA64EA1A4A7EQ40368980-22C39979-D096-4CC7-BFE8-6929724CABA9Q41176091-C69EDFB1-26BB-4844-8900-F3C43D765D04
P50
description
researcher ORCID ID = 0000-0002-3123-0672
@en
name
Scott Stroup
@ast
Scott Stroup
@en
Scott Stroup
@es
Scott Stroup
@nl
type
label
Scott Stroup
@ast
Scott Stroup
@en
Scott Stroup
@es
Scott Stroup
@nl
prefLabel
Scott Stroup
@ast
Scott Stroup
@en
Scott Stroup
@es
Scott Stroup
@nl
P1153
6701317476
P31
P496
0000-0002-3123-0672